Fig. 1

The upregulation of PCGF6 is strongly associated with poor prognosis of patients in pRCC. A H&E staining was used to confirm pRCC and healthy kidney tissues. Scale bar = 25 μm. B The expression of PCGF6 in cancer and healthy kidney tissues was examined by immunohistochemical (IHC) staining. Scale bar = 25 μm. C The protein expression of PCGF6 was detected in tumor (T) and normal (N) kidney tissues using Western blotting. D Quantitative Western blotting of C. E The mRNA level of PCGF6 was explored using RT-qPCR in tumor (n = 31) and healthy kidney (n = 31) tissues. F TCGA database was used to analyze mRNA expression of PCGF6. G Kaplan–Meier analysis of the relationship between the expression level of PCGF6 and patient prognosis in the TCGA database. H The protein expression of PCGF6 was measured using Western blotting in pRCC cell lines (i.e., SKRC-39, Caki-2, ACHN, and UOK-112). I Quantitative analysis of the data from Western blotting of H. J The mRNA level of PCGF6 was measured using RT-qPCR in the aforementioned cell lines. All data are from three independent experiments and are expressed as mean ± standard error. *p < 0.05, **p < 0.01 versus the corresponding controls